All In Biotech

Free tool

FAERS Monitor: Hympavzi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761369 or its brand name (Hympavzi, Marstacimab-Hncq). Reports on generic versions are filed under their own applications.

Reports

103

Serious

55

53% of reports

Hospitalization

21

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • haemarthrosis21
  • haemorrhage18
  • drug dose omission by device9
  • device defective7
  • device failure6
  • epistaxis6
  • contusion5
  • arthralgia4
  • device malfunction4
  • drug ineffective4
  • joint swelling4
  • product dose omission issue4
  • transient ischaemic attack4
  • traumatic haemorrhage4
  • device mechanical issue3

Reports by year received

View as table
YearReports
20245
202534
202664

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,056 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
haemarthrosisSignal21479.6327.39,539
traumatic haemorrhageSignal4435.1166.31,323
device defectiveSignal782.540.3485
device failureSignal680.537.0395
device mechanical issueSignal344.714.788
haemorrhageSignal1835.223.1567
transient ischaemic attackSignal424.29.367
drug dose omission by deviceSignal923.512.6172
epistaxisSignal616.47.572
device malfunctionSignal411.64.429
contusionSignal510.64.535
joint swellingSignal46.82.614
product dose omission issue42.81.13
arthralgia42.00.81
drug ineffective40.60.21

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.